Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167

Watchlist Manager
Jacobio Pharmaceuticals Group Co Ltd Logo
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Watchlist
Price: 1.25 HKD -3.1% Market Closed
Market Cap: 989.7m HKD
Have any thoughts about
Jacobio Pharmaceuticals Group Co Ltd?
Write Note

Jacobio Pharmaceuticals Group Co Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jacobio Pharmaceuticals Group Co Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Long-Term Debt
ÂĄ122m
CAGR 3-Years
293%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Long-Term Debt
ÂĄ1.6B
CAGR 3-Years
4%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Long-Term Debt
ÂĄ2.3B
CAGR 3-Years
17%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Long-Term Debt
ÂĄ127.7m
CAGR 3-Years
N/A
CAGR 5-Years
43%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Long-Term Debt
ÂĄ398.2m
CAGR 3-Years
65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Long-Term Debt
ÂĄ37.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jacobio Pharmaceuticals Group Co Ltd
Glance View

Market Cap
989.7m HKD
Industry
Biotechnology

Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly conducts business within the domestic market.

Intrinsic Value
0.85 HKD
Overvaluation 32%
Intrinsic Value
Price

See Also

What is Jacobio Pharmaceuticals Group Co Ltd's Long-Term Debt?
Long-Term Debt
122m CNY

Based on the financial report for Dec 31, 2023, Jacobio Pharmaceuticals Group Co Ltd's Long-Term Debt amounts to 122m CNY.

What is Jacobio Pharmaceuticals Group Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-26%

Over the last year, the Long-Term Debt growth was -9%. The average annual Long-Term Debt growth rates for Jacobio Pharmaceuticals Group Co Ltd have been 293% over the past three years , -26% over the past five years .

Back to Top